Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038818 · ClinicalTrials.gov registry record · NA
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00038818: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00038818 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038818, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary Objectives: To evaluate response rates of acute or chronic Graft-versus-host disease (GVHD) following CD8 depleted DLI (Depleted Donor Lymphocyte Infusions) in patients with Chronic myelomonocytic leukemia (CMML), chronic lymphoid leukemia (CLL), Non-Hodgkin's lymphoma (NLM), Multiple Myeloma (MM) and Hodgkin's Lymphoma (HD). Secondary Objectives: * To evaluate safety and treatment related mortality after CD8 depleted DLI. * To evaluate the time to onset of GVHD following DLI and response to GVHD treatment. * To evaluate the incidence and timing of pancytopenia following DLI. * To evaluate disease-free survival, overall survival and relapse rates in three cohorts of patients; early relapse CML, late relapse CML and lymphoproliferative disorders (HD, CLL, NHL and MM). * To evaluate the need and efficacy of second or subsequent CD8 depleted donor lymphocyte infusions. * To evaluate the number of apheresis procedures needed to collect appropriate doses of CD4+ cells.
Interventions
- BIOLOGICAL CD8 Depleted Donor Lymphocyte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2001-05 |
| Est. Completion | 2002-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038818
The ClinicalTrials.gov registry entry for NCT00038818 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD8 Depleted Donor Lymphocyte is the first listed.
NCT00038818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038818 about?
NCT00038818 is a clinical study titled "CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation". Primary Objectives: To evaluate response rates of acute or chronic Graft-versus-host disease (GVHD) following CD8 depleted DLI (Depleted Donor Lymphocyte Infusions) in patients with Chronic myelomonocytic leukemia (CMML), chronic lymphoid leukemia (CLL), Non-Hodgkin's lymphoma (NLM), Multiple Myelo...
What is the current status of trial NCT00038818?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2001-05. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00038818?
The interventions under investigation include: CD8 Depleted Donor Lymphocyte (BIOLOGICAL).
Who is sponsoring clinical trial NCT00038818?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.